Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
INCA-033989 by Incyte for Myelofibrosis: Likelihood of Approval
INCA-033989 is under clinical development by Incyte and currently in Phase I for Myelofibrosis. According to GlobalData, Phase I drugs...
Data Insights
INCA-033989 by Incyte for Essential Thrombocythemia: Likelihood of Approval
INCA-033989 is under clinical development by Incyte and currently in Phase I for Essential Thrombocythemia. According to GlobalData, Phase I...